LAURA BRADIGAN: Open Payments
NPI 1407464522 · COMPTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,105 in 49 payments from 15 companies in 2025. Trend: 2023 $3,166 · 2024 $4,401 · 2025 $1,105
Food & beverage: $1,099Education: $5
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 10 | $210 |
| Neurocrine BioSciences, Inc. | 6 | $165 |
| ABBVIE INC. | 7 | $150 |
| Vanda Pharmaceuticals Inc. | 6 | $124 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $89 |
| Alkermes, Inc. | 4 | $85 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
| Corium, LLC | 1 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $32 |
Products named: INGREZZA, VRAYLAR, SPRAVATO, FANAPT, REXULTI, CAPLYTA, ARISTADA, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
